125 related articles for article (PubMed ID: 30847896)
41. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
42. Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Zhao H; Xu L; Yang Y; Shao J; Chen P; Dong X; Gu L; Li D
Acta Haematol; 2017; 137(4):195-200. PubMed ID: 28445872
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P; Roboz GJ; Bulabois CE; Subklewe M; Platzbecker U; Ofran Y; Papayannidis C; Wierzbowska A; Shin HJ; Doronin V; Deneberg S; Yeh SP; Ozcan MA; Knapper S; Cortes J; Pollyea DA; Ossenkoppele G; Giralt S; Döhner H; Heuser M; Xiu L; Singh I; Huang F; Larsen JS; Wei AH
Leukemia; 2021 Jan; 35(1):62-74. PubMed ID: 32203138
[TBL] [Abstract][Full Text] [Related]
44. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
[TBL] [Abstract][Full Text] [Related]
45. Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
Giles F; Rizzieri D; Ravandi F; Swords R; Jacobsen TF; O'Brien S
Leuk Res; 2012 Apr; 36(4):e71-3. PubMed ID: 22226018
[No Abstract] [Full Text] [Related]
46. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
47. Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.
Cavanna L; Di Stasi M; Fornari F; Civardi G; Sbolli G; Moretto M; Buscarini L
Eur J Haematol; 1990 Sep; 45(3):180-1. PubMed ID: 2226733
[No Abstract] [Full Text] [Related]
48. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.
Wang ES; Zeidan A; Tan W; Wilding GE; Ford LA; Wallace PK; Hahn TE; Battiwalla M; McCarthy PL; Wetzler M
Leuk Lymphoma; 2012 Oct; 53(10):2085-8. PubMed ID: 21740302
[No Abstract] [Full Text] [Related]
49. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
50. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Becktell K; Houser K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e38-e40. PubMed ID: 29668549
[TBL] [Abstract][Full Text] [Related]
53. How I treat older patients with acute myeloid leukemia.
Arellano M; Carlisle JW
Cancer; 2018 Jun; 124(12):2472-2483. PubMed ID: 29809277
[No Abstract] [Full Text] [Related]
54. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A
J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139
[TBL] [Abstract][Full Text] [Related]
55. Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
Bertoli S; Tavitian S; Berard E; Gadaud N; Luquet I; Huynh A; Sarry A; Huguet F; Récher C
Leuk Lymphoma; 2019 Jan; 60(1):238-241. PubMed ID: 29893611
[No Abstract] [Full Text] [Related]
56. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
[TBL] [Abstract][Full Text] [Related]
57. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Leonard SM; Perry T; Woodman CB; Kearns P
PLoS One; 2014; 9(1):e87475. PubMed ID: 24489920
[TBL] [Abstract][Full Text] [Related]
58. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
Minderman H; O'Loughlin KL; Smith PF; Pendyala L; Greco WR; Sweeney KG; Ford LA; Wetzler M; Baer MR
Cancer Chemother Pharmacol; 2006 Jan; 57(1):73-83. PubMed ID: 16010591
[TBL] [Abstract][Full Text] [Related]
59. Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.
Godwin CD; Othus M; Powell MA; Buckley SA; Estey EH; Walter RB
Leuk Lymphoma; 2016 Oct; 57(10):2421-4. PubMed ID: 26754357
[No Abstract] [Full Text] [Related]
60. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
